Suspension of trading

Press Releases CureVac

Stocks

CVAC

NL0015436031

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-05 pm EST			5-day change	1st Jan Change
4.660 ^USD	-0.21%		-.--%	+3.10%

Apr. 15	Evotec Taps CureVac Executive as COO	MT
Jan. 06	CureVac ends coverage after BioNTech acquisition

Press Releases

Nov. 25	CureVac Announces Voting Results of Extraordinary General Meeting	EQ
Nov. 24	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates	EQ
25-10-24	CureVac N : Convening Notice EGM 25 November 2025	PU
25-10-24	CureVac N : Proxy Card EGM 25 November 2025	PU
25-10-24	CureVac N : Merger Proposal	PU
25-10-24	CureVac N : Explanatory Notes to the Merger Proposal	PU
25-08-15	CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates	EQ
25-08-07	CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech	EQ
25-06-24	CureVac N : Pressemitteilung	PU
25-06-24	CureVac Announces Voting Results of General Meeting	EQ
25-05-23	CureVac N : Proxy Card AGM 2025	PU
25-05-23	CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2024	PU
25-05-23	CureVac N : Proxycard AGM 2025	PU
25-05-20	CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates	EQ
25-05-15	CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE	EQ
25-04-22	CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Transcript	PU
25-04-10	CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Presentation	PU
25-04-10	CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update	EQ
25-04-08	CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025	EQ
25-04-07	CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer	EQ
25-03-27	CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE	EQ
25-02-18	CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators	EQ
24-11-12	CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Form 6 K	PU
24-11-12	CureVac N : Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Form 6 K	PU
24-11-12	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update	EQ